TY - JOUR
TI - Immunological response to covid‐19 vaccination in ovarian cancer patients receiving parp inhibitors
AU - Liontos, M.
AU - Terpos, E.
AU - Markellos, C.
AU - Zagouri, F.
AU - Briasoulis, A.
AU - Katsiana, I.
AU - Skafida, E.
AU - Fiste, O.
AU - Kunadis, E.
AU - Andrikopoulou, A.
AU - Kaparelou, M.
AU - Koutsoukos, K.
AU - Gavriatopoulou, M.
AU - Kastritis, E.
AU - Trougakos, I.P.
AU - Dimopoulos, M.-A.
JO - Vaccine
PY - 2021
VL - 9
TODO - 10
SP - null
PB - MDPI
SN - 0264-410X
TODO - 10.3390/vaccines9101148
TODO - antivirus agent;  comirnaty;  elasomeran;  neutralizing antibody;  nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor;  niraparib;  olaparib;  rucaparib;  SARS-CoV-2 antibody;  SARS-CoV-2 vaccine;  vaxzevria, adult;  aged;  arthritis;  Article;  asthma;  atrial fibrillation;  cancer patient;  cardiovascular disease;  case control study;  chronic obstructive lung disease;  controlled study;  coronavirus disease 2019;  deep vein thrombosis;  diabetes mellitus;  dyslipidemia;  enzyme linked immunosorbent assay;  female;  glaucoma;  human;  hypertension;  hyperthyroidism;  hypothyroidism;  immune response;  lung disease;  lung embolism;  major clinical study;  male;  metabolic disorder;  middle aged;  osteopenia;  ovary cancer;  prospective study;  vaccination;  very elderly
TODO - Objective: Vaccination for SARS‐CoV‐2 provides significant protection against the infection in the general population. However, limited data exist for cancer patients under systemic ther-apy. Methods: In this cohort, we prospectively enrolled cancer patients treated with PARPi as well as healthy volunteers in order to study the kinetics of anti‐SARS‐CoV‐2 antibodies (NAbs) after COVID‐19 vaccination. Baseline demographics, co‐morbidities, and NAb levels were compared between the two groups. Results: The results of the cohort of 36 patients receiving PARP inhibitors are presented here. Despite no new safety issues being noticed, their levels of SARS‐CoV‐2 neutralizing antibodies were significantly lower in comparison to matched healthy volunteers up to day 30 after the second dose. Conclusions: These results suggest that maintaining precautions against COVID‐19 is essential for cancer patients and should be taken into consideration for the patients under treatment, while further exploration is needed to reduce the uncertainty of SARS‐CoV‐2 immunity among cancer patients under treatment. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
ER -